This study is examining one-time injection of biosimilar pegfilgrastim compared with multiple
injection biosimilar filgrastim post autologous hematopoietic stem cell transplantation.
Study aims to compare biosimilar pegfilgrastim - LaPelga and biosimilar filgrastim -Gastrofil
to see if they are similar in efficacy in terms of neutrophil engraftment, limited adverse
effects, and more convenience to our patients, with potential cost savings.